ArticleJournal of muscle research and cell motility2002
2,3-Butanedione monoxime (BDM) as a myosin inhibitor.
Article in Journal of muscle research and cell motility, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 144 citations in OpenAlex.
- Genetic interrogation reveals mechanisms regulating nexus glia development and shaping heart physiology.Developmental cell · 2026Article
- The pericardium forms as a distinct structure during heart formation.Nature communications · 2025Article
- Hydrogel-Mediated Preservation of Live Tumor Explants for Drug Development in Peritoneal Metastases.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Endothelial cell Piezo1 promotes vascular smooth muscle cell differentiation on large arteries.European journal of cell biology · 2025Article
- CXCR3-CXCL11 Signaling Restricts Angiogenesis and Promotes Pericyte Recruitment.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Endothelial cell Piezo1 promotes vascular smooth muscle cell differentiation on large arteries.bioRxiv : the preprint server for biology · 2024Article
- The influence of internal pressure and neuromuscular agents onFrontiers in bioengineering and biotechnology · 2024Article
- The effect of common paralytic agents used for fluorescence imaging on redox tone and ATP levels in Caenorhabditis elegans.PloS one · 2024Article
- CXCR3-CXCL11 signaling restricts angiogenesis and promotes pericyte recruitment.bioRxiv : the preprint server for biology · 2023Article
- Directionality of developing skeletal muscles is set by mechanical forces.Nature communications · 2023Article
- MyosinA is a druggable target in the widespread protozoan parasite Toxoplasma gondii.PLoS biology · 2023Article
- Signal amplification in growth cone gradient sensing by a double negative feedback loop among PTEN, PI(3,4,5)PMolecular and cellular neurosciences · 2022Article
- Dynamic movement and turnover of extracellular matrices during tissue development and maintenance.Fly · 2022Review
- Mechanical loading of intraluminal pressure mediates wound angiogenesis by regulating the TOCA family of F-BAR proteins.Nature communications · 2022Article
- Article
- Motor Skills: Recruitment of Kinesins, Myosins and Dynein during Assembly and Egress of Alphaherpesviruses.Viruses · 2021Review
- Molecular Mechanisms of the Deregulation of Muscle Contraction Induced by the R90P Mutation in Tpm3.12 and the Weakening of This Effect by BDM and W7.International journal of molecular sciences · 2021Article
- Viability and infectivity ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2020Article
- Article
- Positional Isomers of a Non-Nucleoside Substrate Differentially Affect Myosin Function.Biophysical journal · 2020Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
2,3-Butanedione monoxime (BDM) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II. It has been widely used at millimolar concentrations in cell biological experiments with the assumption that it is an ATPase inhibitor of the myosin superfamily. To determine the usefulness of BDM as a general myosin inhibitor, the ATPase activities of the motor domains of skeletal muscle myosin-II, Acanthamoeba myosin-IC, human myole, chicken myosin-V, and porcine myosin-VI were measured in the presence of 0-40 mM BDM. BDM inhibits skeletal muscle myosin-II, but it does not inhibit the ATPase activity of the other myosins. Therefore, BDM is not a general inhibitor of the myosin ATPase. BDM has a broad effect on many non-myosin proteins (many uncharacterized), and thus should not be used in whole-cell experiments as a myosin inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.